We are currently inviting world-class speakers for the European Congress. Past speakers to the event in Washington DC include:
Jennifer Auchtung, Asst Professor, Therapeutic Microbiology Laboratory, Dept. of Molecular Virology and Microbiology, Baylor College of Medicine
Rosemarie Aurigemma, Chief Biodefense Drug Development Section, NIAID, NIH
Byron Beeler, Board Member, Natural MA
Mr Stefano Bertuzzi, Executive Director/CEO, American Society for Microbiology
Dr Debabrata Biswas, Assistant Professor, University of Maryland University College
Mark Blaskovich, Program Coordinator: Hit Validation & Chemistry, Community for Open Antimicrobial Drug Discovery
Ramiz Boulos, CEO, Boulos & Cooper
Scott Campbell, Corporate Vice President and Chief Regulatory Officer, Cepheid
Henry Chambers III, Chief, Division of Infectious Diseases, SFGH, University of California San Francisco
Thomas Chen, Independent Consultant
Stephen Conafay, Washington Counsel, Antimicrobials Working Group, Principal, The Conafay Group
Dr Nick Conley, Chief Executive Officer, EpiBiome
Christopher L. Cook, PharmD, PhD, Senior Director, Strategic Business Development, Biomerieux, Inc
James Del Rosso, DO, FAOCD, FAAD, ADJ Clinical Professor, (Dermatology), Touro University Nevada
Enea Di Domenico, Clinical Pathology and Microbiology, Istituti Fisioterapici Ospitalieri
Cecilia Dignani, Medical Officer, PSI CRO
Kim Dixon, Health Policy Editor, Politico
Michael Draper, Senior Director, External Science and Partnering, Sanofi
Michael Dudley, Senior VP of Research and Development and CSO, The Medicines Company
Jens Eckstein, President, S.R. One
Barry Eisenstein, Distinguished Physician, Antimicrobials, Merck & Co.
Robert Eisinger, Senior Health Science Policy Advisor, Division of Program Coordination, Planning, and Strategic Initiatives,, NIH
Marcos Espinal, Director, Dept of Communicable Diseases and Health Analysis, PAHO/WHO
Scott Evans, Director, Statistical and Data Management Center (SDMC) for the Antibacterial Resistance Leadership Group (ARLG), Harvard University
Tamar Ghosh, Lead, Longitude Prize, Nesta
Steven Gilman, Chairman & CEO, Contrafect Corporation
Vikas Gupta, Director, Clinical Strategy, MedMined Services, Becton Dickinson
Judy Hackett, Project Coordinator, Drive-AB, Global Payer Evidence Director, AstraZeneca
Chris Houchens, PhD, Branch Chief (Acting), Antibacterials Program, BARDA
David Huang, Chief Medical Officer, Motif Bio
Hasan Jafri, Sr. Director, Clinical R&D, Infectious Diseases and Vaccines MedImmune, AstraZeneca,Coordinator, COMBACTE, Innovative Medicines Initiative
Evan Jones, Chairman and Chief Executive Officer, OpGen Inc
Anders Karlén, Managing Entity, ENABLE, Professor in Computer-aided Drug Design, Uppsala University
Barbara Kerstiens, Deputy Head of Unit, Fighting Infectious Diseases and Advancing Public Health Research and Innovatio, European Commission
Dr Jane Knisely, Program Officer, Bacteriology and Mycology Branch, NIAID, NIH - NIAID
Michael Koeris, Chief Executive Officer, Sample6
Laura Kovanda, Director and Global Development Project Leader for Infectious Diseases, Astellas Pharma U.S.
Jenelle krishnamoorthy, Executive Director, U.S. Policy and Government Relations, Merck
Joe Larsen, Acting Deputy Director, BARDA
Mr David Larwood, CEO and Founder, Valley Fever Solutions
Frédéric Laurent, Professor of Microbiology, National Reference Center on Staphylococcus, University Hospital, Lyon
Gabriela Lavezzari, Research Director, Margolis Center for Health Policy, Duke University
Bohyung Lee, Biofilm R&D, Biofilm Control
James Liang, Professor, Dept. of Biomedical Engineering, Chemistry and Biology, Stevens Institute of Technology
Bert Lopansri, MD, Intermountain Medical Center and LDS Hospital, University of Utah School of Medicine
David Mantus, Chief Development Officer, Arsanis Inc
Anthony McDonnell, Head of Economic Research, Review on Antimicrobial Resistance
Randy D Milby, Chief Executive Officer, CorMedix Inc.
Mr Neil Miller, Chief Scientific Officer, Auspherix Ltd
Sumathi Nambiar, Director, Division of Aniti-Infective Products, FDA
Dawn O'Connell, Deputy Chief of Staff, United States Department of Health & Human Services
Professor Kevin Outterson, Professor of Health Law, Bioethics and Human Rights, Boston University School of Law
Mr Steve Parkinson, President and Chief Executive Officer, Lakewood-Amedex Inc.
Jean Patel, Deputy Director, Office of Antimicrobial Resistance, Center for Disease Control & Prevention
Robin Patel, Professor of Microbiology and Medicine, Mayo Clinic
Edmund Pezalla, VP, Aetna Pharmacy Management
Jesse Pines, Director of the George Washington Center for Healthcare Innovation and Policy Research, George Washington University School of Medicine & Health Sciences
Aleks Radovic-Moreno, Senior Associate, PureTech Health
Chad Roy, Chief Executive Officer, Asepticys
Ms Elyse Seltzer, Chief Medical Officer, Nabriva Therapeutics
Ribhi Shawar, Branch Chief, Division of Microbiology, CDRH OIR FDA
Melissa Stundick, Head of Strategic Alliances, Spero Therapeutics LLC
Mr Malcolm Thomas, COO, Agile Sciences, Inc.
Luigi Toma, Clinical Pathology and Microbiology, Istituti Fisioterapici Ospitalieri
Mr Larry Tsai, VP, Clinical Development, Tetraphase Pharmaceuticals
Vincent Tumminello, Director, Market Access, Biomerieux, Inc
Mr Lucas Wiarda, Global Marketing Director & Head of Sustainable Antibiotics Program, DSM Sinochem Pharmaceuticals
Barry Wohl, CBO, SymbalRx
Mr John Woloszyn, President & Chief Executive Officer, Intralytix Inc.
Robert Yancey, Jr., Infectious Diseases Consultant, Antibiotic Adjuvant, Inc
Zachary Zimmerman, CEO, Forge Therapeutics
APPLY TO SPEAK